Author Archives: Oriana Schwindt
Takeda Changes Dexlansoprazole Brand Name From Kapidex to Dexilant
Takeda’s US subsidiary launched its proton pump inhibitor dexlansoprazole last February under the name Kapidex. No one thought they’d have to find a new name a year later.
But shortly after the launch, the company began getting reports of dispensing errors. Some were due to prescription misreading, others to simple, honest mistakes. The two drugs causing [...]
Posted in Corporate Responsibility, FDA, Marketing, News, Safety, Strategy Tagged Casodex, chronic pain, Dexilant, dexlansoprazole, dispensing error, FDA, Kadian, Kapidex, Prostate cancer, proton pump inhibitor, Takeda 2 Comments
Merck, Lilly, Pfizer: One for All and All for One
Just a month after Andrew Witty’s announcement that GSK will make more than 13,500 of its malaria compounds available to all, Pfizer, Merck, and Eli Lilly have thrown their do-gooder hats into the ring as well.
Together, the three drug giants will pull together an undisclosed dollar amount in seed funding and create the independent, non-profit [...]
Posted in Strategy Tagged ACRG, Andrew Witty, Cancer, Diseases & Conditions, Eli Lilly, Health, Lung cancer, Pfizer 1 Comment
HBA Names Woman of the Year
GSK’s Deirdre Connelly has been named the Healthcare Businesswomen’s Association’s Woman of the Year for 2010. Connelly, who just passed the one-year mark as president of GSK’s North American pharmaceuticals unit, is the 21st woman to win the organization’s “WOTY” award, which comes on the heels of another honor: She was ranked #37 in Fortune’s [...]
Posted in Corporate Responsibility, News, People, leadership Tagged Deirdre Connelly, Eli Lilly, GSK, HBA, WOTY Leave a comment
Tweeting to Your Facebook: Why Pharma Is So Bad With Social Media
For those of you who didn’t know, it’s Social Media Week. Granted, the week is almost over, but the panel that you all care about didn’t take place until yesterday afternoon here in NYC.
The panel’s mouthful of a name—“Navigating Social Media & New Technology in Healthcare & Pharmaceutical Industries”—is nevertheless an accurate description of the [...]
Posted in E-Media, Marketing Tagged adverse events, DJ Edgerton, Facebook, Jay Parkinson, Lipitor, Marketing, Saatchi, social media, Twitter, Zemoga 5 Comments

Updated IMS Forecast Predicts Market Growth